Friday, November 24, 2023
Er-Kim Pharmaceuticals, an international pharmaceutical company specializing in the commercialization of novel therapies, has joined the effort to combat antimicrobial resistance (AMR) by participating in World AMR Awareness Week. This global campaign, previously known as World Antimicrobial Awareness Week (WAAW), occurs annually from November 18 to 24. The rise of resistant bacteria worldwide poses a serious threat to the efficacy of existing antibiotics. Er-Kim Pharmaceuticals recognizes the need for industry collaboration and the development of innovative products to ensure access to life-saving treatments for patients globally.
A joint report by the European Centre for Disease Prevention and Control (ECDC) and the WHO Regional Office for Europe underscores AMR as a significant public health concern in the WHO European region. Disturbingly, estimates from the European Union/European Economic Area (EU/EEA) reveal over 670,000 infections annually due to antibiotic-resistant bacteria, leading to approximately 33,000 deaths.
Current market conditions and traditional business models present challenges in making new AMR products accessible to patients in need. This issue not only adversely affects patients in the U.S. and Western markets but millions globally, particularly in emerging markets where resistance rates are significantly higher. Er-Kim Pharmaceuticals advocates for a new approach that prioritizes high-need emerging markets, emphasizing both substantial volume and pricing opportunities.
Er-Kim Pharmaceuticals, observes, "Most new AMR treatments are introduced in the U.S. and Western Europe, where prices are high, and usage is low. However, there is a considerable unmet need and untapped market in other territories that fall between low and high-income countries, presenting a greater number of people who can benefit from AMR products."
Er-Kim, emphasizes, "The world urgently requires more antibiotics. The Western world can play a pivotal role by collaborating with territories outside their markets to develop and distribute essential treatments. There is undoubtedly a market for AMR products, and it is imperative for all industry participants and the financial community to reassess their commercial approaches and acknowledge underprioritized markets through collaborative efforts."
Er-Kim Pharmaceuticals is taking a leading role in the battle against AMR, concentrating on the development and distribution of new treatments in high-need markets. Their strategy involves establishing commercial partnerships for innovative antibiotics and creating targeted distribution networks in emerging markets. Additionally, Er-Kim is launching stewardship programs to promote sustainable antibiotic use.
The company calls on industry peers and financial partners to join forces in redefining pharmaceutical approaches, placing a priority on public health, especially in underserved regions. Together, they aim to effectively address the global challenge of antimicrobial resistance.
Source: globenewswire.com
